Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients-Reference-Cited by-同舟云学术

Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients

Published:2016-03-07 Issue:4 Volume:7 Page:458-466
ISSN:2190-5991
Container-title:Journal of Cachexia, Sarcopenia and Muscle
language:en
Short-container-title:Journal of Cachexia, Sarcopenia and Muscle

Author:

Rutten Iris J.G.¹²,van Dijk David P.J.³⁴,Kruitwagen Roy F.P.M.¹²,Beets-Tan Regina G.H.²⁵⁶,Olde Damink Steven W.M.³⁴,van Gorp Toon¹²

Affiliation:

1. Department of Obstetrics and Gynaecology; Maastricht University Medical Centre; 6202 AZ Maastricht The Netherlands

2. GROW School for Oncology and Developmental Biology; Maastricht University; 6200 MD Maastricht The Netherlands

3. Department of General Surgery; Maastricht University Medical Centre; 6202 AZ Maastricht The Netherlands

4. NUTRIM School of Nutrition and Translational Research in Metabolism; Maastricht University; 6200 MD Maastricht The Netherlands

5. Department of Radiology; Maastricht University Medical Centre; 6202 AZ Maastricht The Netherlands

6. Department of Radiology; Netherlands Cancer Institute; 1006 BE Amsterdam The Netherlands

Publisher

Wiley

Subject

Physiology (medical),Orthopedics and Sports Medicine

Reference36 articles.

1. Ferlay J Soerjomataram I Ervik M Dikshit R Eser S Mathers C et al GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase 2013

2. Surveillance, Epidemiology, and End Results (SEER) Program SEER 9 Incidence & U.S. Mortality Research Data 1973-2011 In: National Cancer Institute D, Surveillance Research Program, Surveillance Systems Branch

3. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study;De Angelis;Lancet Oncol,2014

4. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO);Bois;Cancer,2009

5. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote;N Engl J Med,2010

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of a combined exercise and dietary intervention on clinical outcomes in patients with ovarian cancer: the Physical Activity and Dietary intervention in OVArian cancer (PADOVA) randomized controlled trial;International Journal of Gynecologic Cancer;2024-09-07

2. The impact of chemotherapy on adipose tissue remodeling: The molecular players involved in this tissue wasting;Biochimie;2024-08

3. AI-based volumetric six-tissue body composition quantification from CT cardiac attenuation scans enhances mortality prediction: multicenter study;2024-08-01

4. Interpretable machine learning model based on clinical factors for predicting muscle radiodensity loss after treatment in ovarian cancer;Supportive Care in Cancer;2024-07-24

5. Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: a pooled analysis of 10 retrospective studies;BMC Cancer;2024-07-11